APVO 1.61 ▼ -1.23% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Aptevo Therapeutics Inc.

    NASDAQ: APVO · Real-Time Price · USD
    1.61
    -0.02 (-1.23%)
    At close: Sep 05, 2025, 3:59 PM
    1.60
    -0.62%
    After-hours: Sep 05, 2025, 07:38 PM EDT
    -1.23%
    Bid 1.54
    Market Cap 9.29M
    Revenue (ttm) n/a
    Net Income (ttm) -24.02M
    EPS (ttm) 2585.37
    PE Ratio (ttm) n/a
    Forward PE -0.01
    Analyst Buy
    Ask 1.65
    Volume 144,164
    Avg. Volume (20D) 2,251,875
    Open 1.63
    Previous Close 1.63
    Day's Range 1.54 - 1.64
    52-Week Range 1.54 - 381.10
    Beta 5.77

    About APVO

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol APVO
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for APVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    2 months ago
    +81.91%
    Aptevo Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
    3 months ago
    -21.05%
    Aptevo Therapeutics shares are trading lower after the company announced a 1-for-20 reverse stock split.
    news image

    2 days ago · accessnewswire.com

    Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

    New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppres...

    news image

    3 weeks ago · accessnewswire.com

    Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

    Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS...

    news image

    3 weeks ago · accessnewswire.com

    Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

    Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types ...

    news image

    2 months ago · accessnewswire.com

    Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

    SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on...

    news image

    2 months ago · accessnewswire.com

    Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

    Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipl...

    news image

    2 months ago · benzinga.com

    Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

    U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.

    news image

    2 months ago · marketwatch.com

    Aptevo More Than Doubles After Favorable Results in Leukemia Study

    Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia s...

    news image

    2 months ago · benzinga.com

    Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

    Aptevo Therapeutics Inc APVO stock is surging on Wednesday.

    news image

    2 months ago · accessnewswire.com

    Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

    SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro...

    news image

    2 months ago · accessnewswire.com

    Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

    85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed ...

    Add to Watchlist